Clear answers to common questions about Gaucher disease
There are three main clinical types:
• Type 1 – the most common form and generally does not involve primary disease of the central nervous system.
• Type 2 – a severe, rapidly progressive form with neurological involvement, usually beginning in infancy.
• Type 3 – a neurological form that generally progresses more slowly than Type 2 and can continue into adulthood.
The symptoms and severity can vary considerably between individuals.
There are three main clinical types:
• Type 1 – the most common form and generally does not involve primary disease of the central nervous system.
• Type 2 – a severe, rapidly progressive form with neurological involvement, usually beginning in infancy.
• Type 3 – a neurological form that generally progresses more slowly than type 2 and can continue into adulthood.
The symptoms and severity can vary considerably between individuals.
Symptoms vary depending on the type of Gaucher disease and from person to person.
They can include:
• Tiredness and anaemia
• Easy bruising or bleeding
• An enlarged spleen or liver
• Bone pain or bone complications
• Neurological symptoms in types 2 and 3
Some people, particularly those with type 1 Gaucher disease, may have few or no symptoms for many years.
Yes, but this depends on the type.
Type 1 Gaucher disease does not generally involve primary central nervous system disease. Types 2 and 3 are known as neuronopathic Gaucher disease because they involve the central nervous system. The neurological features and their progression can differ considerably between individuals.
Yes. Gaucher disease is an autosomal recessive genetic condition. A person generally needs to inherit a disease-causing variant in the relevant gene from both parents to develop Gaucher disease. A person who inherits one disease-causing variant is generally a carrier and does not develop Gaucher disease.
A carrier has one disease-causing variant in the GBA1 gene and one working copy. Carriers generally do not develop Gaucher disease themselves, but they can pass the variant on to their children. If both parents are carriers, there is a 25% chance in each pregnancy of having a child affected by Gaucher disease, a 50% chance of having a child who is a carrier, and a 25% chance of inheriting neither of the familial variants.
Yes. Because Gaucher disease is inherited in an autosomal recessive manner, an affected person can pass a disease-causing GBA1 variant to their children.
If an affected person has children with someone who is not a carrier of a disease-causing GBA1 variant, their children would generally inherit one variant and be carriers rather than have Gaucher disease. If their partner is also a carrier or is affected, the risks are different and should be discussed with a genetics professional.
If Gaucher disease has been diagnosed in your family, speak with your healthcare professional about your family history and whether genetic or enzyme testing may be appropriate.
Testing can help establish whether someone is affected or is a carrier, and genetic counselling can help families understand inheritance and reproductive implications.
Diagnosis usually involves demonstrating low glucocerebrosidase enzyme activity, typically using a blood sample, together with genetic testing where appropriate.
Additional tests may be used to understand how Gaucher disease is affecting a person’s organs, bones and overall health.
Diagnosis can be delayed because many Gaucher symptoms are non-specific and may initially be attributed to more common conditions.
Learn more: Diagnosis →
Yes. Gaucher disease can be diagnosed in children or adults, depending on the type and when symptoms become apparent. Some people with type 1 Gaucher disease may have few symptoms and remain undiagnosed for many years.
Diagnosis can be delayed because many Gaucher symptoms are non-specific and may initially be attributed to more common conditions.
There is currently no cure for Gaucher disease, but treatments are available that can manage many manifestations of the condition.
Treatment options include enzyme replacement therapy (ERT) and substrate reduction therapy (SRT) for appropriate patients. Supportive treatment may also be needed for particular symptoms or complications.
The main disease-specific treatments are:
• Enzyme replacement therapy (ERT), which provides the missing enzyme; and
• Substrate reduction therapy (SRT), which reduces the production of the substance that accumulates in Gaucher disease.
Other treatments may be used to manage specific complications, such as bone disease and pain. Treatment options vary according to the type of Gaucher disease and individual circumstances.
Treatment effects depend on the type of Gaucher disease and the particular symptoms being treated.
ERT and SRT can be used for appropriate people with type 1 Gaucher disease. ERT may also help with some of the visceral manifestations of type 3 Gaucher disease, but it does not prevent or reverse the primary neurological disease. Type 2 Gaucher disease has severe neurological involvement for which current disease-specific treatments do not alter the underlying neurological progression.
For some people receiving ERT, treatment may be possible at home. Availability and eligibility vary between countries and healthcare systems.
The specific arrangements for home treatment should be discussed with the treating healthcare team.
Yes. Bone involvement is an important feature of Gaucher disease, particularly type 1, and can include bone pain, reduced bone density, bone infarction, osteonecrosis and fractures.
Bone disease can require specific monitoring and treatment in addition to disease-specific therapy.
No. Gaucher disease has a wide range of clinical presentations. Some people, particularly those with type 1 disease, may have few or no symptoms, while others can experience significant effects on their health.
Gaucher disease can affect people in very different ways. The IGA's information is designed to help patients, families and caregivers understand the condition and have informed conversations with their healthcare teams.
Registered Charity Number: 1192011
Company Limited by Guarantee Registered in England & Wales No. 06653373
This website is supported by our funders. The International Gaucher Alliance maintains full editorial independence, and our funders have no influence over the content published on this website.
© 2026 International Gaucher Alliance. All rights reserved.